NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC): who owns it and who trades it
As of Oct 30, 2026, NMTC insiders reported 6 open-market sales worth $54.9K and 2 purchases worth $737K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mark Christianson (Director), with $54.9K.
Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, NMTC insiders reported $737K of open-market purchases and $54.9K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | David J. Wambeke | Chief Business Officer | Purchase | 33,333 | $2.01 | $67K | Form 4 |
| Jun 30, 2026 | Mark Christianson | Director | Sale | 10,000 | $3.18 | $31.8K | Form 4 |
| Mar 30, 2026 | Mark Christianson | Director | Sale | 15,363 | $0.74 | $11.4K | Form 4 |
| Mar 13, 2026 | Mark Christianson | Director | Sale | 100 | $0.80 | $80 | Form 4 |
| Mar 12, 2026 | Mark Christianson | Director | Sale | 817 | $0.80 | $654 | Form 4 |
| Mar 11, 2026 | Mark Christianson | Director | Sale | 2,109 | $0.80 | $1.7K | Form 4 |
| Mar 10, 2026 | Mark Christianson | Director | Sale | 11,611 | $0.80 | $9.3K | Form 4 |
| Mar 1, 2026 | David J. Wambeke | Chief Business Officer | Purchase | 1.00M | $0.67 | $670K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| David J. Wambeke | Chief Business Officer | $737K | – | Aug 27, 2026 |
| Mark Christianson | Business Development Director | – | $54.9K | Jun 30, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
NMTC short interest
Low short interest. 2.4% of NMTC shares are sold short: about 1 share in 42. Over the last 12 reports the number of shares short went up 357%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 207,063 NMTC shares were sold short, 2.4% of the shares outstanding, down 0.1% from the report before. At the average daily volume of 86,817 shares, buying them all back would take about 2.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 207,063 | 2.38% | -0% | 86,817 | 2.4 |
| Oct 15, 2026 | 207,315 | 2.38% | +16% | 208,871 | 1.0 |
| Sep 30, 2026 | 178,730 | 2.05% | +136% | 150,116 | 1.2 |
| Sep 15, 2026 | 75,782 | 0.87% | -69% | 114,269 | 1.0 |
| Aug 31, 2026 | 242,435 | 2.79% | +195% | 1.36M | 1.0 |
| Aug 14, 2026 | 82,079 | 0.94% | +112% | 102,758 | 1.0 |
| Jul 31, 2026 | 38,703 | 0.44% | +219% | 34,041 | 1.1 |
| Jul 15, 2026 | 12,127 | 0.14% | -58% | 25,743 | 1.0 |
| Jun 30, 2026 | 28,845 | 0.33% | -32% | 36,514 | 1.0 |
| Jun 15, 2026 | 42,342 | 0.49% | +25% | 25,224 | 1.7 |
| May 29, 2026 | 33,927 | 0.39% | -25% | 35,293 | 1.0 |
| May 15, 2026 | 45,302 | 0.53% | +63% | 37,277 | 1.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Neuroone Medical Technologies company events
Neuroone Medical Technologies filed 14 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, restatement). The latest was on Oct 5, 2026.
- Oct 5, 2026AnnouncementThe Company reported the following preliminary, unaudited fiscal year 2026 financial and operational results: ● Achieved annual total revenue of approximately $10.5 million for the year ended September 30, 2026. ● Achieved quarterly revenue of approximately $3.8 million for the quarter ended… Filing
- Aug 27, 2026AnnouncementNeuroOne Medical Technologies Corporation issued a press release announcing that three procedures in large animals were performed using the Company’s StereoCED™ platform. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jun 12, 2026AnnouncementNeuroOne Medical Technologies Corporation entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC pursuant to which the Company may sell from time to time shares of its common stock, par value $0.001 through any method permitted that is deemed an “at the… Filing
- May 22, 2026RestatementThe Audit Committee of the Board of Directors of NeuroOne Medical Technologies Corporation, after discussion with management, determined that the Company’s previously issued interim financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026… Filing
- May 12, 2026ResultsReleased financial results. Filing
- May 4, 2026AnnouncementAs previously reported, on May 6, 2025, NeuroOne Medical Technologies Corporation received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC notifying the Company that because the closing bid price per share of the Company’s common stock was below $1.00… Filing
- Apr 30, 2026LeadershipRonald McClurg notified NeuroOne Medical Technologies Corporation of his intention to retire as the Company’s Chief Financial Officer. Filing
- Apr 14, 2026RulesChanged its bylaws or articles. Filing
- Apr 3, 2026LeadershipThe Board of Directors of NeuroOne Medical Technologies Corporation adopted a First Amendment to the NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan. Filing
- Feb 25, 2026AnnouncementMade another announcement. Filing
- Feb 17, 2026ResultsReleased financial results. Filing
- Dec 22, 2025LeadershipThe Board of Directors of the Company voted to increase the size of the Board to five members and voted to appoint Jason R. Mills to the Board as a Class I director to fill the vacancy created by the increase in Board size, effective December 18, 2025. Filing
- Dec 17, 2025ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Neuroone Medical Technologies financials
Questions about NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) stock
Are NMTC insiders buying or selling?
In the last 12 months, NMTC insiders reported 2 open-market purchases worth $737K and 6 sales worth $54.9K. The latest trade was on Aug 27, 2026. See every trade.
What is the short interest in NMTC?
As of Oct 30, 2026, 207,063 NMTC shares were sold short, 2.4% of the shares outstanding, down 0.1% from the report before. At the average daily volume of 86,817 shares, buying them all back would take about 2.4 trading days (days to cover). See the history.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.